ArticleWorld journal of stem cells2026
Breast cancer stem cell activity driven by
Article in World journal of stem cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is one of the most prevalent malignancies affecting women worldwide, with approximately 2.3 million new cases diagnosed annually. Breast cancer stem cells (BCSCs) play pivotal roles in tumor initiation, progression, metastasis, therapeutic resistance, and disease recurrence. Cancer stem cells possess self-renewal capacity, multipotent differentiation potential, and enhanced tumorigenic activity, but their molecular characteristics and regulatory mechanisms require further investigation.
aimTo comprehensively characterize the molecular features of BCSCs through multi-omics approaches, construct a prognostic prediction model based on stem cell-related genes, reveal cell-cell communication networks within the tumor microenvironment, and provide theoretical foundation for personalized treatment strategies.
methodsFlow cytometry was employed to detect the expression of BCSC surface markers (CD34, CD45, CD29, CD90, CD105). Transcriptomic analysis was performed to identify differentially expressed genes. Least absolute shrinkage and selection operator regression analysis was utilized to screen key prognostic genes and construct a risk scoring model. Single-cell RNA sequencing and spatial transcriptomics were applied to analyze tumor heterogeneity and spatial gene expression patterns. Cell-cell communication network analysis was conducted to reveal interactions between stem cells and the microenvironment.
resultsFlow cytometric analysis revealed the highest expression of CD105 (96.30%), followed by CD90 (68.43%) and CD34 (62.64%), while CD29 showed lower expression (7.16%) and CD45 exhibited the lowest expression (1.19%). Transcriptomic analysis identified 3837 significantly differentially expressed genes (1478 upregulated and 2359 downregulated). Least absolute shrinkage and selection operator regression analysis selected 10 key prognostic genes, and the constructed risk scoring model effectively distinguished between high-risk and low-risk patient groups (
conclusionThis study comprehensively characterized the molecular features of BCSCs through multi-omics approaches, identified reliable surface markers and key regulatory genes, and constructed a prognostic prediction model with clinical application value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.